Cryoviva Life Sciences has introduced PrepaCyte-CB technology in India through an exclusive partnership, bringing a globally recognized cord blood processing platform to the country. The move is aimed at improving the quality of cord blood stem cell preservation and supporting future clinical applications of regenerative medicine.
The company says the launch represents a shift in focus from simply storing cord blood to preserving stem cells that maintain higher quality, functionality, and long-term therapeutic value.
For many years, cord blood banking has largely focused on storage. However, as regenerative medicine continues to develop, healthcare providers and researchers are paying greater attention to the quality and usability of the preserved stem cells.
Cryoviva believes that the future of stem cell banking depends not only on preserving cells but also on ensuring those cells remain clinically relevant and ready for potential therapeutic use when needed.
With the introduction of PrepaCyte-CB, Indian families will now have access to a technology that aligns with advanced cord blood processing standards used in major healthcare markets, including the United States, Europe, and Singapore.
According to Cryoviva, PrepaCyte-CB has demonstrated several advantages over conventional cord blood processing methods.
Scientific studies and comparative observations associated with the technology have shown:
The technology has also demonstrated faster neutrophil engraftment trends. Recovery has been observed in approximately 18 to 21 days, compared to 24 to 28 days typically reported with older processing methods.
These factors are considered important because they may influence the effectiveness and readiness of stem cells for future medical applications.
Focus on Higher-Quality Stem Cell Preservation
Speaking about the development, Dr. Alok Khullar, Group CEO of RJ Corp Healthcare, which includes Cryoviva Life Sciences and Cocoon Hospitals, said the industry needs to move beyond the idea of preservation alone.
According to Dr. Khullar, the next phase of stem cell banking should focus on preserving stem cells that are purer, stronger, functional, and clinically meaningful for future therapeutic applications.
He noted that bringing PrepaCyte-CB technology to India is an important step toward raising the standards of cord blood processing and providing Indian families access to globally advanced regenerative healthcare solutions.
Integration with Advanced Automation Systems
Cryoviva is also integrating PrepaCyte-CB with advanced automation platforms such as LMB Supernova. The company says this combination is expected to improve standardization, precision, and consistency throughout the cord blood processing workflow.
By reducing variability and improving processing outcomes, the company aims to deliver stem cell preservation that meets evolving clinical and scientific expectations.
Growing Importance of Regenerative Medicine
As regenerative medicine continues to gain momentum worldwide, the quality of preserved stem cells is becoming increasingly important. Healthcare providers are placing greater emphasis on recovery rates, cell viability, and long-term functionality rather than focusing solely on storage capacity.
Cryoviva says the introduction of PrepaCyte-CB reflects this changing landscape and supports a broader industry transition toward preserving stem cells with stronger therapeutic potential and clinical utility.
A New Direction for Stem Cell Banking in India
The launch of PrepaCyte-CB technology marks a significant development for India's stem cell banking sector. By introducing globally benchmarked processing standards, Cryoviva aims to help improve the quality of cord blood preservation and support the future needs of regenerative medicine.
The company believes this approach will help shift the conversation from storing cord blood to preserving stem cells that are better prepared for potential clinical use in the years ahead.